SEARCH

SEARCH BY CITATION

References

  • Akaneya Y. and Tsumoto T. (2006) Bidirectional trafficking of prostaglandin E2 receptors involved in long-term potentiation in visual cortex. J. Neurosci. 26, 1020910221.
  • Andreasson K. I., Savonenko A., Vidensky S. et al. (2001) Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice. J. Neurosci. 21, 81988209.
  • Araki H., Ukawa H., Sugawa Y., Yagi K., Suzuki K. and Takeuchi K. (2000) The roles of prostaglandin E receptor subtypes in the cytoprotective action of prostaglandin E2 in rat stomach. Aliment. Pharmacol. Ther. 14(Suppl. 1), 116124.
  • Chakrabarty P., Jansen-West K., Beccard A. et al. (2010) Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J. 24, 548559.
  • Choi J. S., Kim H. Y., Chun M. H., Chung J. W. and Lee M. Y. (2006) Expression of prostaglandin E2 receptor subtypes, EP2 and EP4, in the rat hippocampus after cerebral ischemia and ischemic tolerance. Cell Tissue Res. 324, 203211.
  • Haass C. (2004) Take five-BACE and the gamma-secretase quartet conduct Alzheimer’s amyloid beta-peptide generation. EMBO J. 23, 483488.
  • Haass C. and Selkoe D. J. (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101112.
  • Hawkey C. J. (2000) Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 119, 521535.
  • Heneka M. T., Sastre M., Dumitrescu-Ozimek L. et al. (2005) Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128, 14421453.
  • Ho L., Purohit D., Haroutunian V. et al. (2001) Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. Arch. Neurol. 58, 487492.
  • Hoshino T., Nakaya T., Homan T. et al. (2007) Involvement of prostaglandin E2 in production of amyloid-beta peptides both in vitro and in vivo. J. Biol. Chem. 282, 3267632688.
  • Hoshino T., Namba T., Takehara M., Nakaya T., Sugimoto Y., Araki W., Narumiya S., Suzuki T. and Mizushima T. (2009) Prostaglandin E2 stimulates the production of amyloid-beta peptides through internalization of the EP4 receptor. J. Biol. Chem. 284, 1849318502.
  • Huang S. M., Mouri A., Kokubo H. et al. (2006) Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J. Biol. Chem. 281, 1794117951.
  • Ikonomovic M. D., Uryu K., Abrahamson E. E. et al. (2004) Alzheimer’s pathology in human temporal cortex surgically excised after severe brain injury. Exp. Neurol. 190, 192203.
  • Imbimbo B. P., Solfrizzi V. and Panza F.. (2010) Are NSAIDs useful to treat Alzheimer’s disease or mild cognitive impairment?. Front. Aging Neurosci. 2, 114.
  • Kabashima K., Saji T., Murata T. et al. (2002) The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J. Clin. Invest. 109, 883893.
  • Kanninen K., Heikkinen R., Malm T. et al. (2009) Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer’s disease. Proc. Natl Acad. Sci. USA 106, 1650516510.
  • Kitamura Y., Shimohama S., Koike H., Kakimura J., Matsuoka Y., Nomura Y., Gebicke-Haerter P. J. and Taniguchi T. (1999) Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer’s disease brains. Biochem. Biophys. Res. Commun. 254, 582586.
  • Kobayashi K., Noda Y., Matsushita N. et al. (2000) Modest neuropsychological deficits caused by reduced noradrenaline metabolism in mice heterozygous for a mutated tyrosine hydroxylase gene. J. Neurosci. 20, 24182426.
  • Kotilinek L. A., Westerman M. A., Wang Q. et al. (2008) Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain 131, 651664.
  • Liang X., Wang Q., Hand T., Wu L., Breyer R. M., Montine T. J. and Andreasson K. (2005) Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer’s disease. J. Neurosci. 25, 1018010187.
  • Mattson M. P. (2004) Pathways towards and away from Alzheimer’s disease. Nature 430, 631639.
  • Montine T. J., Sidell K. R., Crews B. C., Markesbery W. R., Marnett L. J., Roberts L. J. 2nd and Morrow J. D. (1999) Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 53, 14951498.
  • Qin W., Ho L., Pompl P. N. et al. (2003) Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity. J. Biol. Chem. 278, 5097050977.
  • Ray W. A., Griffin M. R. and Stein C. M. (2004) Cardiovascular toxicity of valdecoxib. N. Engl. J. Med. 351, 2767.
  • Roberson E. D., Scearce-Levie K., Palop J. J., Yan F., Cheng I. H., Wu T., Gerstein H., Yu G. Q. and Mucke L. (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model. Science 316, 750754.
  • Savonenko A., Munoz P., Melnikova T., Wang Q., Liang X., Breyer R. M., Montine T. J., Kirkwood A. and Andreasson K. (2009) Impaired cognition, sensorimotor gating, and hippocampal long-term depression in mice lacking the prostaglandin E2 EP2 receptor. Exp. Neuro. 217, 6373.
  • Shaftel S. S., Kyrkanides S., Olschowka J. A., Miller J. N., Johnson R. E. and O’Banion M. K. (2007) Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J. Clin. Invest. 117, 15951604.
  • Shi J., Johansson J., Woodling N. S., Wang Q., Montine T. J. and Andreasson K. (2010) The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J. Immunol. 184, 72077218.
  • Singh D. (2004) Merck withdraws arthritis drug worldwide. BMJ 329, 816.
  • Sisodia S. S. and St George-Hyslop P. H. (2002) Gamma-Secretase, Notch, Abeta and Alzheimer’s disease: where do the presenilins fit in? Nat. Rev. Neurosci. 3, 281290.
  • Smith C. J., Zhang Y., Koboldt C. M. et al. (1998) Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl Acad. Sci. USA 95, 1331313318.
  • Srinivasan B. D. and Kulkarni P. S. (1989) Inhibitors of the arachidonic acid cascade in the management of ocular inflammation. Prog. Clin. Biol. Res. 312, 229249.
  • Takeuchi K., Yagi K., Kato S. and Ukawa H. (1997) Roles of prostaglandin E-receptor subtypes in gastric and duodenal bicarbonate secretion in rats. Gastroenterology 113, 15531559.
  • Tegeder I., Pfeilschifter J. and Geisslinger G. (2001) Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 15, 20572072.
  • Terada N., Shimizu Y., Kamba T. et al. (2010) Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. Cancer Res. 70, 16061615.
  • Tomita S., Kirino Y. and Suzuki T. (1998) Cleavage of Alzheimer’s amyloid precursor protein (APP) by secretases occurs after O-glycosylation of APP in the protein secretory pathway. Identification of intracellular compartments in which APP cleavage occurs without using toxic agents that interfere with protein metabolism. J. Biol. Chem. 273, 62776284.
  • Van Dam D., D’Hooge R., Staufenbiel M., Van Ginneken C., Van Meir F. and De Deyn P. P. (2003) Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur. J. Neurosci. 17, 388396.
  • Vane J. R. and Botting R. M. (1996) Mechanism of action of anti-inflammatory drugs. Scand. J. Rheumatol. Suppl. 102, 921.
  • in t’ Veld B. A., Ruitenberg A., Hofman A., Launer L. J., van Duijn C. M., Stijnen T., Breteler M. M. and Stricker B. H. (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N. Engl. J. Med. 345, 15151521.
  • Vitolo O. V., Sant’Angelo A., Costanzo V., Battaglia F., Arancio O. and Shelanski M. (2002) Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc. Natl Acad. Sci. USA 99, 1321713221.
  • Wyss-Coray T. (2006) Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med. 12, 10051015.
  • Yan Q., Zhang J., Liu H., Babu-Khan S., Vassar R., Biere A. L., Citron M. and Landreth G. (2003) Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer’s disease. J. Neurosci. 23, 75047509.
  • Yao C., Sakata D., Esaki Y., Li Y., Matsuoka T., Kuroiwa K., Sugimoto Y. and Narumiya S. (2009) Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat. Med. 15, 633640.
  • Yoshida K., Oida H., Kobayashi T. et al. (2002) Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proc. Natl Acad. Sci. USA 99, 45804585.